Holen Sie sich die Stockscreener-App
41.96
3.71%
1.50
Handel nachbörslich:
41.96
Schlusskurs vom Vortag:
$40.46
Offen:
$40.38
24-Stunden-Volumen:
900.01K
Relative Volume:
0.93
Marktkapitalisierung:
$2.82B
Einnahmen:
$2.82B
Nettoeinkommen (Verlust:
$-1.87B
KGV:
-1.5039
EPS:
-27.9
Netto-Cashflow:
$-96.80M
1W Leistung:
+3.43%
1M Leistung:
-5.15%
6M Leistung:
-6.78%
1J Leistung:
-10.51%
1-Tages-Spanne:
$40.38
$42.06
1-Wochen-Bereich:
$39.90
$42.50
52-Wochen-Spanne:
$29.73
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Firmenname
Quidelortho Corporation
Sektor
Branche
Telefon
(858) 552-1100
Adresse
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Vergleichen Sie QDEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
41.96 | 2.82B | 2.82B | -1.87B | -96.80M | -27.90 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-09-19 | Fortgesetzt | UBS | Neutral |
| 2024-09-05 | Hochstufung | Craig Hallum | Hold → Buy |
| 2024-03-04 | Herabstufung | UBS | Neutral → Sell |
| 2024-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-14 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-19 | Eingeleitet | Citigroup | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Sell |
| 2022-06-17 | Fortgesetzt | JP Morgan | Neutral |
| 2022-02-22 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-03-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Bestätigt | Barclays | Overweight |
| 2018-01-04 | Hochstufung | CL King | Neutral → Buy |
| 2017-09-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Bestätigt | Canaccord Genuity | Hold |
| 2017-02-17 | Eingeleitet | CL King | Neutral |
| 2016-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Bestätigt | Barclays | Overweight |
| 2016-02-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-12-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Eingeleitet | Barclays | Overweight |
| 2013-07-31 | Bestätigt | Canaccord Genuity | Buy |
| 2011-03-03 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Quidelortho Corporation Aktie (QDEL) Neueste Nachrichten
Inside QuidelOrtho's Growth Strategy: Key Insights Coming at Raymond James Conference - StockTitan
QuidelOrtho Corporation f/k/a Quidel Corporation Class Action: Levi & Korsinsky Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 – QDEL - ACCESS Newswire
QuidelOrtho Co. (NASDAQ:QDEL) Shares Purchased by State of New Jersey Common Pension Fund D - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) Shareholders - ACCESS Newswire
Shareholders that lost money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
QuidelOrtho: Growth Struggles And Negative GAAP Earnings Continue To Disinterest Investors - Seeking Alpha
$30+ Bn Primary Care POC Diagnostics Market Opportunities - GlobeNewswire
Why QuidelOrtho Stock Bounced More Than 4% Higher Today - MSN
QDEL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Corporation Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
QuidelOrtho Co. (NASDAQ:QDEL) Sees Significant Decrease in Short Interest - MarketBeat
In vitro diagnostics Market Poised for Significant Growth to Reach value of USD 133.24 Billion from 2025 to 2034 - GlobeNewswire Inc.
January 2026 Options Now Available For QuidelOrtho (QDEL) - Nasdaq
QuidelOrtho Co. (NASDAQ:QDEL) Receives $51.20 Average PT from Analysts - MarketBeat
QDEL Stock Earnings: QuidelOrtho Misses EPS, Beats Revenue for Q1 2024 - MSN
QuidelOrtho's SWOT analysis: stock poised for growth amid challenges - MSN
Stephens Inc. AR Acquires Shares of 14,915 QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QDEL DEADLINE ALERT: Bernstein Liebhard LLP Reminds QuidelOrtho Corporation Investors of Upcoming Deadline - ACCESS Newswire
QuidelOrtho (NASDAQ:QDEL) Trading Down 4.9% Following Analyst Downgrade - MarketBeat
QuidelOrtho (NASDAQ:QDEL) Shares Gap Up Following Analyst Upgrade - MarketBeat
QuidelOrtho (NASDAQ:QDEL) Price Target Raised to $45.00 - MarketBeat
18,856 Shares in QuidelOrtho Co. (NASDAQ:QDEL) Acquired by Legato Capital Management LLC - MarketBeat
QuidelOrtho (NASDAQ:QDEL) Cut to Hold at StockNews.com - MarketBeat
QuidelOrtho's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Corporation Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
QuidelOrtho (NASDAQ:QDEL) Issues FY 2025 Earnings Guidance - MarketBeat
QuidelOrtho (NASDAQ:QDEL) Issues Quarterly Earnings Results, Misses Estimates By $0.44 EPS - MarketBeat
QuidelOrtho projects $2.6B-$2.81B revenue for 2025 supported by cost savings and margin expansion - MSN
QuidelOrtho (NASDAQ:QDEL) Announces Quarterly Earnings Results - MarketBeat
QuidelOrtho 2025 EPS, revenue guidance ranges include consensus - MSN
QuidelOrtho Full Year 2024 Earnings: EPS Misses Expectations - Simply Wall St
Lightrock Netherlands B.V. Takes $10.05 Million Position in QuidelOrtho Co. (NASDAQ:QDEL) - MarketBeat
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates - MSN
QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2024 Earnings Call Transcript - MSN
Quidel Announces Revised Agreement for Its Pending Acquisition of Alere’s B-type Naturietic Peptide (BNP) Assay Bus. Run on... - br.ADVFN.com
QuidelOrtho’s Earnings Call: Mixed Sentiment Amidst Revenue Decline - TipRanks
QDELQuidel and bioMerieux Announce a Global Strategic Alliance in Rapid Diagnostics - br.ADVFN.com
Where QuidelOrtho Stands With Analysts - Benzinga
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract - Yahoo Finance
UBS Raises Price Target on QuidelOrtho to $45 From $43, Maintains Neutral Rating - Marketscreener.com
Finanzdaten der Quidelortho Corporation-Aktie (QDEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):